We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

International Biotechnology Trust plc (IBT) Ordinary 25p Shares

Sell:666.00p Buy:678.00p 0 Change: No change
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:666.00p
Buy:678.00p
Change: No change
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:666.00p
Buy:678.00p
Change: No change
Market closed Prices as at close on 26 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Security Weight
Incyte Corp 6.61%
Amgen Inc 5.77%
Gilead Sciences Inc 5.55%
Vera Therapeutics Inc Class A 5.01%
Sv Fund Vi Investment 4.91%
Intra-Cellular Therapies Inc 4.63%
Supernus Pharmaceuticals Inc 4.60%
Biomarin Pharmaceutical Inc 4.35%
AstraZeneca PLC ADR 3.67%
Ultragenyx Pharmaceutical Inc 3.51%
Sector Weight
Healthcare 105.40%
Country Weight
United States 88.97%
Canada 3.98%
United Kingdom 3.95%
Netherlands 3.30%
Sweden 1.95%
China 1.48%
Denmark 1.19%
Switzerland 0.42%
Ireland 0.16%

Fee Structure

Management fee payable monthly at the rate of 0.9% p.a. of the NAV. The performance fee on the unquoted pool is 20% of net realised gain performance fee on the quoted pool is 10% of relative outperformance above the sterling-adjusted NBI plus a 0.5% hurdle. Investment Management Agreement is terminable by either party on 12 months written notice.

Dividend Policy

The Board introduces an annual dividend, equals to 4% of the last day NAV of the financial year. Dividends are paid to shareholders semi-annually on January and August each year. Paying the dividend out of capital returns gives the shareholders a differentiated source of income from most other income generating investments, that is not affected by fluctuations in yield from the portfolio companies.

ASSET SPLIT

Total number of holdings: 87.

Trust Manager

Ailsa Craig

Manager Bio

Not currently available for this investment trust.

Board Of Directors

Kate Cornish-BowdenChairman, Gillian Elcock, Caroline Gulliver, Patrick Maxwell, Patrick Magee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.